Patents by Inventor Olaf Mundigl

Olaf Mundigl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USE
    Publication number: 20240101657
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Application
    Filed: November 15, 2023
    Publication date: March 28, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ROLAND BECKMANN, JOERG BENZ, STEFAN DENGL, CHRISTIAN GASSNER, GUIDO HARTMANN, PETER MICHAEL HUELSMANN, SABINE IMHOF-JUNG, KRISTIAN HOBOLT JENSEN, HUBERT KETTENBERGER, STEFAN LORENZ, JOERG MOELLEKEN, OLAF MUNDIGL
  • Antibody that binds to VEGF and IL-1beta and methods of use
    Patent number: 11866490
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: January 9, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Joerg Benz, Stefan Dengl, Christian Gassner, Guido Hartmann, Peter Michael Huelsmann, Sabine Imhof-Jung, Kristian Hobolt Jensen, Hubert Kettenberger, Stefan Lorenz, Joerg Moelleken, Olaf Mundigl
  • HUMANIZED ANTI-TAU(PS422) ANTIBODIES AND METHODS OF USE
    Publication number: 20230265177
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: December 29, 2022
    Publication date: August 24, 2023
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Humanized anti-Tau(pS422) antibodies and methods of use
    Patent number: 11572404
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: February 7, 2023
    Assignee: Hoffman-La Rocher Inc.
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
    Patent number: 11273223
    Abstract: Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: March 15, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Guy Georges, Olaf Mundigl, Jens Niewoehner
  • ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USE
    Publication number: 20220041707
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Application
    Filed: September 8, 2021
    Publication date: February 10, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ROLAND BECKMANN, JOERG BENZ, STEFAN DENGL, CHRISTIAN GASSNER, GUIDO HARTMANN, PETER MICHAEL HUELSMANN, SABINE IMHOF-JUNG, KRISTIAN HOBOLT JENSEN, HUBERT KETTENBERGER, STEFAN LORENZ, JOERG MOELLEKEN, OLAF MUNDIGL
  • Antibody that binds to VEGF and IL-1beta and methods of use
    Patent number: 11130804
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: September 28, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Joerg Benz, Stefan Dengl, Christian Gassner, Guido Hartmann, Peter Michael Huelsmann, Sabine Imhof-Jung, Kristian Hobolt Jensen, Hubert Kettenberger, Stefan Lorenz, Joerg Moelleken, Olaf Mundigl
  • HUMANIZED ANTI-TAU(PS422) ANTIBODIES AND METHODS OF USE
    Publication number: 20210139571
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: September 17, 2020
    Publication date: May 13, 2021
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES
    Publication number: 20210069338
    Abstract: Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.
    Type: Application
    Filed: May 13, 2020
    Publication date: March 11, 2021
    Inventors: Ulrich Brinkmann, Guy Georges, Olaf Mundigl, Jens Niewoehner
  • Humanized anti-tau(pS422) antibodies and methods of use
    Patent number: 10822402
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: November 3, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
    Patent number: 10806795
    Abstract: Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: October 20, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Guy Georges, Olaf Mundigl, Jens Niewoehner
  • Blood-Brain Barrier Shuttles Containing Antibodies Recognizing Alpha-Synuclein
    Publication number: 20200299397
    Abstract: The invention provides blood-brain barrier shuttles comprising monoclonal antibody 5C1 and related antibodies linked to a monovalent binding entity for a blood-brain barrier receptor. The 5C1 antibody binds to an epitope within residues 118-126 of alpha-synuclein. The antibodies are useful, for example, for treating and/or diagnosing synucleinopathies including Lewy body diseases, such as Parkinson's disease, diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).
    Type: Application
    Filed: February 6, 2020
    Publication date: September 24, 2020
    Inventors: Robin Barbour, Kate Dora Games-Thiel, Tarlochan S. Nijjar, Wagner Zago, Olaf Mundigl, Jens Niewoehner, Georg Tiefenthaler
  • Bispecific antibodies and methods of use in ophthalmology
    Patent number: 10730938
    Abstract: Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: August 4, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Olaf Mundigl, Joerg Thomas Regula, Ralf Schumacher, Barbara Weiser
  • HUMANIZED ANTI-TAU(PS422) ANTIBODIES AND METHODS OF USE
    Publication number: 20200223912
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: September 9, 2019
    Publication date: July 16, 2020
    Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
  • ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USE
    Publication number: 20200199214
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Application
    Filed: December 20, 2019
    Publication date: June 25, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ROLAND BECKMANN, JOERG BENZ, STEFAN DENGL, CHRISTIAN GASSNER, GUIDO HARTMANN, PETER MICHAEL HUELSMANN, SABINE IMHOF-JUNG, KRISTIAN HOBOLT JENSEN, HUBERT KETTENBERGER, STEFAN LORENZ, JOERG MOELLEKEN, OLAF MUNDIGL
  • Anti-alpha-synuclein antibodies and methods of use
    Patent number: 10647761
    Abstract: The invention provides anti-human alpha-synuclein antibodies and methods of using the same.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: May 12, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Klaus Kaluza, Olaf Mundigl, Thomas Kremer, Markus Britschgi, Sylwia Huber
  • Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
    Patent number: 10562973
    Abstract: The invention provides blood-brain barrier shuttles comprising monoclonal antibody 5C1 and related antibodies linked to a monovalent binding entity for a blood-brain barrier receptor. The 5C1 antibody binds to an epitope within residues 118-126 of alpha-synuclein. The antibodies are useful, for example, for treating and/or diagnosing synucleinopathies including Lewy body diseases, such as Parkinson's disease, diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: February 18, 2020
    Assignees: Prothena Bioscience Limited, Hoffmann-LaRoche Inc.
    Inventors: Robin Barbour, Kate Dora Games-Thiel, Tarlochan S. Niijar, Wagner Zago, Olaf Mundigl, Jens Niewoehner, Georg Tiefenthaler
  • Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
    Patent number: 10561737
    Abstract: Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: February 18, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Brinkmann, Guy Georges, Olaf Mundigl, Jens Niewoehner
  • BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES
    Publication number: 20200000929
    Abstract: Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.
    Type: Application
    Filed: March 1, 2019
    Publication date: January 2, 2020
    Inventors: Ulrich Brinkmann, Guy Georges, Olaf Mundigl, Jens Niewoehner
  • Humanized anti-Tau(pS422) antibodies and methods of use
    Patent number: 10465000
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: November 5, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger